Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)
Anke H.E.M. Klerkx(Amsterdam UMC Location University of Amsterdam), John J.P. Kastelein(QRx Pharma (United States)), J. Wouter Jukema(Leiden University Medical Center), Aeilko H. Zwinderman(Amsterdam Neuroscience), Greetje J. de Grooth(Radboud University Nijmegen), J.A. Kuivenhoven(Amsterdam UMC Location University of Amsterdam)
Cited by 103
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k